Evidence map›Paper›PMID 41542172›Full record

ArticleBiochemistry and biophysics reports2025

Regulatory interplay of cyclin D1 and INSM1 in suppressing INSL6 expression: Implications for breast cancer biology.

Kozo Homma, Takuya Hasegawa, Shizuka Umezu, Kazumichi Osawa, Hisanori Sato, Koji Sato, Toshiyuki Sakamaki

Abstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kozo HommaLaboratory of Health Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, 956-8603, Japan.
Takuya HasegawaLaboratory of Health Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, 956-8603, Japan.
Shizuka UmezuLaboratory of Health Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, 956-8603, Japan.
Kazumichi OsawaLaboratory of Health Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, 956-8603, Japan.
Hisanori SatoLaboratory of Health Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, 956-8603, Japan.
Koji SatoLaboratory of Health Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, 956-8603, Japan.
Toshiyuki SakamakiLaboratory of Health Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, 956-8603, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclin D1, a key regulator of the G1-to-S phase cell cycle transition, is frequently amplified or overexpressed in breast cancer, contributing to tumorigenesis. Beyond its canonical role in cell cycle regulation, Cyclin D1 forms a complex with INSM1, a zinc-finger transcriptional repressor implicated in neuroendocrine differentiation. Here, we identify insulin-like peptide 6 (

Indexed as

Breast cancerCyclin D1INSL6INSM1

Identifiers

PMID41542172
PMCPMC12803796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.